Alzamend Neuro logo

Alzamend Neuro

ALZN | NASDAQ
Chart Builder DCF Calculator
$1.18
-$0.06 (-4.84%)
At close: Nov 16, 2026, 4:00 PM ET
$1.16
-$0.02 (-1.69%)
After-hours: Nov 16, 2026, 6:04 PM ET
-4.84%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
39
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #549/1021 (Top 54%)

Key Statistics

Market Data

Market Cap $5.69M
1D Range
1.11 1.28
52W Range
0.86 2.44

Valuation (TTM)

PE -0.51
PB 0.98
EV/EBITDA 0.21

Valuation (NTM)

Forward PE N/A
Forward PEG 0.01
Price Target $26.00
Loading financial charts...

Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, ...

Sector Healthcare
Industry Biotechnology
Employees 6
IPO Date Jun 15, 2021
Fiscal Year May - April

Latest News

No news articles available yet.

Analyst Summary

# of Analysts
1
Consensus
Buy
Price Target
$26.00
Upside
+2103.39%
Buy (1)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.